Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 24,750 followers.

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study https://t.co/6v2qUdkAwx https://t.co/03mr33AUkd

04 Jan 2023

Reply Repost Favourite

RT @FrontOncology: New research: Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-…

04 Jan 2023

Reply Repost Favourite

New research: Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study: Purpose To investigate the impact of metabolic syndrome (MetS) on pathologic complete response (pCR) and… https://t.co/6

04 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.